Core Viewpoint - Fosun Pharma's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration of China for the listing application of Enzalutamide soft capsules, which are indicated for the treatment of high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) and symptomatic or asymptomatic metastatic castration-resistant prostate cancer (CRPC) in adult patients who have failed androgen deprivation therapy (ADT) [1] Group 1 - Enzalutamide is an androgen receptor inhibitor that acts on the androgen receptor signaling pathway, competitively inhibiting the binding of androgens to androgen receptors, thereby suppressing androgen receptor nuclear translocation and the interaction between androgen receptors and DNA [1] - The primary metabolite of Enzalutamide, N-desmethyl-Enzalutamide, exhibits similar in vitro activity to Enzalutamide [1] - Enzalutamide has been shown to inhibit the proliferation of prostate cancer cells and induce apoptosis in vitro, and it can reduce tumor volume in mouse models of prostate cancer xenografts [1]
福森药业：“恩扎卢胺软胶囊”获批上市